Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 18 of the 39 sources its claims cite were checked for support.
Abstract
In Candida albicans , Upc2 is a zinc-cluster transcription factor that targets genes, including those of the ergosterol biosynthesis pathway. To date, three documented UPC2 gain-of-function (GOF) mutations have been recovered from fluconazole-resistant clinical isolates that contribute to an increase in ERG11 expression and decreased fluconazole susceptibility. In a group of 63 isolates with reduced susceptibility to fluconazole, we found that 47 overexpressed ERG11 by at least 2-fold over the average expression levels in 3 unrelated fluconazole-susceptible strains. Of those 47 isolates, 29 contained a mutation in UPC2 , whereas the remaining 18 isolates did not. Among the isolates containing mutations in UPC2 , we recovered eight distinct mutations resulting in putative single amino acid substitutions: G648D, G648S, A643T, A643V, Y642F, G304R, A646V, and W478C. Seven of these resulted in increased ERG11 expression, increased cellular ergosterol, and decreased susceptibility to fluconazole compared to the results for the wild-type strain. Genome-wide transcriptional analysis was performed for the four strongest Upc2 amino acid substitutions (A643V, G648D, G648S, and Y642F). Genes commonly upregulated by all four mutations included those involved in ergosterol biosynthesis, in oxidoreductase activity, the major facilitator efflux pump encoded by the MDR1 gene, and the uncharacterized ATP binding cassette transporter CDR11 . These findings demonstrate that gain-of-function mutations in UPC2 are more prevalent among clinical isolates than previously thought and make a significant contribution to azole antifungal resistance, but the findings do not account for ERG11 overexpression in all such isolates of C. albicans .
Overview
CoChat Summary
TL;DR
In a collection of azole-resistant *Candida albicans* clinical isolates, *ERG11* overexpression was common, and many such isolates carried gain-of-function mutations in *UPC2*. Seven of eight recovered Upc2 substitutions increased *ERG11* expression, cellular ergosterol, and resistance to fluconazole and other ergosterol biosynthesis inhibitors, but *UPC2* mutations did not explain all *ERG11* overexpression.
Key findings
- Among 63 isolates with reduced fluconazole susceptibility, 47 overexpressed *ERG11* by at least 2-fold; 29 of those 47 had a *UPC2* mutation, while 18 did not.
- Eight distinct putative Upc2 amino acid substitutions were recovered: G648D, G648S, A643T, A643V, Y642F, G304R, A646V, and W478C; seven increased *ERG11* expression, increased cellular ergosterol, and decreased fluconazole susceptibility, whereas G304R did not.
- In constructed strains, homozygous mutant *UPC2* alleles generally produced stronger *ERG11* expression and lower azole susceptibility than heterozygous strains; G648D gave the highest *ERG11* expression.
- Microarray analysis of four strong *UPC2* GOF alleles (A643V, G648D, G648S, Y642F) found 61 commonly upregulated and 5 commonly downregulated genes, including ergosterol biosynthesis genes, oxidoreductase genes, *MDR1*, and *CDR11*.
Methods
- Used 72 unrelated clinical *C. albicans* isolates from the University of Iowa, including oral and nonoral sources; fluconazole resistance was defined as MIC ≥ 16 µg/ml, and *ERG11*, *CDR1*, *CDR2*, and *MDR1* expression was measured by qRT-PCR.
- Sequenced *UPC2* alleles from isolates overexpressing *ERG11*, then constructed *C. albicans* strains expressing mutant *UPC2* alleles alone, as heterozygotes with wild-type *UPC2*, and as homozygotes using the SAT1-flipper system.
- Measured antifungal MICs by modified CLSI broth microdilution and Etest, quantified cellular ergosterol spectrophotometrically, and performed genome-wide transcriptional profiling with Affymetrix *C. albicans* custom expression arrays.
Limitations
- The paper states that it cannot define the clinical implications of fluconazole resistance among nonoral isolates, that *ERG11* expression levels in clinical isolates did not always match those in laboratory strains constructed with the same *UPC2* allele, and that not all *ERG11* overexpression was explained by *UPC2* GOF mutations.
- The paper states that other regulators of ergosterol biosynthesis, *UPC2* promoter mutation, *UPC2* duplication, trans-acting mutations, or aneuploidy such as chromosome 5 duplication/chr5L isochromosome may contribute, and that combinatorial effects of activated *UPC2* with mutant *ERG11* alleles were not explored.
- Evident from the text: most mechanistic work used laboratory-constructed strains rather than the original clinical isolates, so the direct clinical impact of each individual *UPC2* allele remains inferential.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 2 Not valid · 10 Not checked · 90 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In Candida albicans , Upc2 is a zinc-cluster transcription factor that targets genes, including those of the ergosterol biosynthesis pathway.”
- Also stated in: § Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans · boosted
“Alternately, the zinc-cluster transcription factor Upc2 has been shown to regulate the expression of ERG11 and other genes involved in ergosterol biosynthesis (19, 30).”
What the sources say
- Supportedcites [19] 19. MacPherson S, et al. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob. Agents Chemother. 49 :1745-1752. source
The Results identify C. albicans Upc2p as a member of the zinc-cluster family of transcriptional regulators. The Results and Discussion report its binding to an ERG2 promoter element and its role in regulating ergosterol-biosynthesis genes. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [30] 30. Silver PM, Oliver BG, White TC. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell 3 :1391-1397. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans · boosted
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“As seen with TAC1 or MRR1 mutations, a loss-of-heterozygosity event that results in two GOF alleles, either by a mitotic recombination event between homologous chromosomes or by a loss of a chromosome combined with a duplication of the homologous chromosome, would provide an advantage when challenged with antifungals (2, 22).”
What the sources say
- Not checked — no full text of the sourcecites [2] 2. Coste AT, et al. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172 :2139-2156. source
- Supportedcites [22] 22. Morschhauser J, et al. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3 :e164. doi:10.1371/journal.ppat.0030164. source
The Discussion states that two mutated MRR1 alleles produce greater drug resistance than one and that this advantage during antimycotic therapy can select for loss of heterozygosity. It also names mitotic recombination and chromosome loss followed by duplication as routes to that loss. This paper supports the MRR1 portion of the sentence; the TAC1 example has a separate citation. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of those isolates that did overexpress MDR1 , even fewer isolates expressed MDR1 to the levels previously observed in azole-resistant isolates (22).”
What the sources say
- Supportedcites [22] 22. Morschhauser J, et al. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3 :e164. doi:10.1371/journal.ppat.0030164. source
The citation supports the benchmark of MDR1 overexpression in azole-resistant isolates, not the citing authors’ count of how many of their isolates reached it. In the Results section on MRR1 and MDR1 expression (page not provided), the source reports MDR1 overexpression in fluconazole-resistant clinical isolates F5, G5, and 6692 relative to susceptible isolates. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“ERG11 is transcriptionally regulated by the zinc cluster transcription factor Upc2.”
What the sources say
- Partly supportedcites [4] 4. Crowley JH, Leak FW, Jr, Shianna KV, Tove S, Parks LW. 1998. A mutation in a purported regulatory gene affects control of sterol uptake in Saccharomyces cerevisiae. J. Bacteriol. 180 :4177-4183. sourceExperimental — accuracy not yet measured
The Abstract identifies UPC2 as a gene encoding a protein with a Zn(II)2Cys6 DNA-binding motif, and the Discussion describes it as a predicted member of that regulatory protein family. Neither passage establishes that Upc2 transcriptionally regulates ERG11; a search for ERG11 found no passage addressing that relationship. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As has been previously observed in UPC2 GOF mutations, aminoacidsubstitutions resulting from activating mutations were localized near the C terminus, where the activation domain of zinc-cluster transcription factors is found (18).”
What the sources say
- Supportedcites [18] 18. MacPherson S, Larochelle M, Turcotte B. 2006. A fungal family of transcriptional regulators: the zinc cluster proteins. Microbiol. Mol. Biol. Rev. 70 :583-604. source
The Introduction states that the activation domain is most often C-terminal and identifies a gain-of-function UPC2 mutation, Gly888Asp, within that domain. It also reports gain-of-function mutations in the activation domains of other zinc-cluster proteins. The paper describes one specific UPC2 mutation, rather than multiple UPC2 substitutions. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
61 more claims
Create a free account to see all 116 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 31
- It may state two separate claims as one. 27
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many ERG11 mutations seem to interfere with drug binding and to decrease susceptibility in an additive manner36.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CaUpc2, the primary transcriptional activator of CaERG11 and other ergosterol biosynthetic pathway genes [16].”
From The Candida glabrata Upc2A transcription factor is a global regulator of antifungal drug resistance pathways (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, mutations in this pathway, causing alterations in enzymes activity or drug binding sites, are major factors which are related with azole resistance.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the ERG11 and ERG3 genes or the UPC2 gene which encodes a transcription factor contribute to azole resistance.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast, gain-of-function mutations in UPC2 often lead to high expression of ERG11 and make a signi fi cant contribution to azole resistance.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [46]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ RESULTS
“From our collection of 72 isolates, 9 were classified as fluconazole susceptible, while the remaining isolates were resistant.”
§ MATERIALS AND METHODS
“| 1-10 | N/A | Azole susceptible | University of Iowa | | 11-72 | N/A | Azole resistant | University of Iowa |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ MATERIALS AND METHODS
“pUPC2-W467C”
§ MATERIALS AND METHODS
“| 25B2D1 | UPC2M4A | UPC2 W478C ::FRT/ UPC2 W478C ::FRT | This study |”
Citations
Cites
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353 · cited 1×
“albicans by the interplay of several mechanisms of resistance (17, 21, 23, 32).”
BackgroundA rapid and simple method for preparation of RNA from Saccharomyces cerevisiae
Schmitt, M. E., Brown, T. A., & Trumpower, B. L. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.10.3091 · Cited by 1,338
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Klein, R. S., Harris, C. A., Small, C. B., Moll, B., Lesser, M., & Friedland, G. H. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408093110602 · Cited by 863 · cited 2×
“Candida albicans is an opportunistic fungal pathogen thatcauses mucosal, cutaneous, and systemic infections, including oropharyngeal candidiasis (OPC), the most frequent infection in people with AIDS (9, 13).”
BackgroundSanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 1×
“Overexpression of the efflux transporter genes CDR1, CDR2, and MDR1 is a common mechanism of drug resistance in this organism (10, 17, 26).”
BackgroundThe SAT1 flipper, an optimized tool for gene disruption in Candida albicans
Reuß, O., Vik, Å., Kolter, R., & Morschhäuser, J. (2004) · Gene · doi:10.1016/j.gene.2004.06.021 · Cited by 742 · cited 4×
“For selection of strains containing the SAT1-flipper cassette (25), nourseothricin (200 g/ ml) was added to YPD agar plates.”
BackgroundMethodInfluentialSelf-citationAneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733 · cited 1×
“ERG11 gene amplification by chromosome 5 duplication or the presence of a chr5L isochromosome is known to contribute to azole resistance (29).”
BackgroundA Fungal Family of Transcriptional Regulators: the Zinc Cluster Proteins
MacPherson, S., Larochelle, M., & Turcotte, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00015-06 · Cited by 612 · cited 1×
“As has been previously observed in UPC2 GOF mutations, amino acid substitutions resulting from activating mutations were localized near the C terminus, where the activation domain of zinc-cluster transcription factors is found (18).”
BackgroundAntifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · cited 1×
“albicans by the interplay of several mechanisms of resistance (17, 21, 23, 32).”
BackgroundRangel‐Frausto, M. S., Wiblin, T., Blumberg, H. M., Saiman, L., Patterson, J., Rinaldi, M., Pfaller, M., Edwards, Jr., Jarvis, W., Dawson, J., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/520194 · Cited by 430
Coste, A. T., Karababa, M., Ischer, F., Bille, J., & Sanglard, D. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1639-1652.2004 · Cited by 407
Coste, A., Turner, V., Ischer, F., Morschhäuser, J., Forche, A., Selmecki, A., Berman, J., Bille, J., & Sanglard, D. (2006) · Genetics · doi:10.1534/genetics.105.054767 · Cited by 385 · cited 1×
“As seen with TAC1 or MRR1 mutations, a loss-of-heterozygosity event that results in two GOF alleles, either by a mitotic recombination event between homologous chromosomes or by a loss of a chromosome combined with a duplication of the homologous chromosome, would provide an advantage when challenged with antifungals…”
BackgroundSelf-citationMorschhäuser, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J., Homayouni, R., & Rogers, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030164 · Cited by 355 · cited 7×
“As seen with TAC1 or MRR1 mutations, a loss-of-heterozygosity event that results in two GOF alleles, either by a mitotic recombination event between homologous chromosomes or by a loss of a chromosome combined with a duplication of the homologous chromosome, would provide an advantage when challenged with antifungals…”
BackgroundMethodResultInfluentialSelf-citationDunkel, N., Blaß, J., Rogers, P. D., & Morschhäuser, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06309.x · Cited by 278 · cited 3×
“Likewise, Mrr1 has been identified as the regulator of the major facilitator superfamily (MFS) transporter Mdr1 in azole-resistant isolates, and specific mutations in this transcriptional regulator result in its constitutive activation, leading to the overexpression of Mdr1 (6, 22).”
BackgroundSelf-citationMacPherson, S., Akache, B., Weber, S., De Deken, X., Raymond, M., & Turcotte, B. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1745-1752.2005 · Cited by 238 · cited 1×
“Alternately, the zinc-cluster transcription factor Upc2 has been shown to regulate the expression of ERG11 and other genes involved in ergosterol biosynthesis (19, 30).”
BackgroundFeigal, D. W., Katz, M. H., Greenspan, D., Westenhouse, J., Winkelstein, W., Lang, W., Samuel, M., Buchbinder, S. P., Hessol, N. A., Lifson, A. R., et al. (1991) · AIDS · doi:10.1097/00002030-199105000-00007 · Cited by 237
The genetic basis of fluconazole resistance development in Candida albicans
Morschhäuser, J. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00087-x · Cited by 237 · cited 1×
“albicans by the interplay of several mechanisms of resistance (17, 21, 23, 32).”
BackgroundSelf-citationDunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J., & Rogers, P. D. (2008) · Eukaryotic Cell · doi:10.1128/ec.00103-08 · Cited by 236 · cited 8×
“The standard error was calculated from CT values as previously described (7).”
BackgroundMethodInfluentialSelf-citationRole of Candida albicans Transcription Factor Upc2p in Drug Resistance and Sterol Metabolism
Silver, P. M., Oliver, B. G., & White, T. C. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1391-1397.2004 · Cited by 216 · cited 1×
“Alternately, the zinc-cluster transcription factor Upc2 has been shown to regulate the expression of ERG11 and other genes involved in ergosterol biosynthesis (19, 30).”
BackgroundLopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White, T. C., Sanglard, D., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2932 · Cited by 210 · cited 2×
“Overexpression of the efflux transporter genes CDR1, CDR2, and MDR1 is a common mechanism of drug resistance in this organism (10, 17, 26).”
BackgroundHeilmann, C. J., Schneider, S., Barker, K. S., Rogers, P. D., & Morschhäuser, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-09 · Cited by 142 · cited 1×
“Previous studies show that activating mutations in Upc2 result in increased expression of ERG11 and decreased fluconazole susceptibility; however, only three substitutions (G648D, A643T, and A643V) in Upc2 have been identified in clinical isolates that contribute to azole resistance (7, 11, 12).”
BackgroundSelf-citationSchubert, S., Barker, K. S., Znaidi, S., Schneider, S., Dierolf, F., Dunkel, N., Aïd, M., Boucher, G., Rogers, P. D., Raymond, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01343-10 · Cited by 135 · cited 1×
“Upc2 has previously been shown to bind to the promoter of the drug efflux pump MDR1 but was not a cause of Mdr1-mediated drug resistance (28, 33).”
BackgroundSelf-citationMolecular aspects of fluconazole resistance development in Candida albicans
Franz, R., Ruhnke, M., & Morschhäuser, J. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00498.x · Cited by 129 · cited 1×
“Overexpression of the efflux transporter genes CDR1, CDR2, and MDR1 is a common mechanism of drug resistance in this organism (10, 17, 26).”
BackgroundSelf-citationA Role for Sterol Levels in Oxygen Sensing in Saccharomyces cerevisiae
Davies, B. S. J., & Rine, J. (2006) · Genetics · doi:10.1534/genetics.106.059964 · Cited by 123 · cited 2×
“Previous work in S. cerevisiae shows that ScUpc2 and ScEcm22 are localized to intracellular membranes outside the nucleus, and under sterol-depleting conditions, perinuclear localization is increased (20).”
BackgroundCrowley, J. H., Leak, F. W., Shianna, K. V., Tove, S., & Parks, L. W. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.16.4177-4183.1998 · Cited by 123
Znaidi, S., Weber, S., Zin Al-Abdin, O., Bomme, P., Saidane, S., Drouin, S., Lemieux, S., De Deken, X., Robert, F., & Raymond, M. (2008) · Eukaryotic Cell · doi:10.1128/ec.00070-08 · Cited by 119 · cited 2×
“Interestingly, UPC2 was not found to be upregulated in any of the four strains analyzed by microarray analysis, although Upc2 is thought to autoregulate and has been shown to bind its own promoter in experiments using chromatin immunoprecipitation with microarray technology (ChIP-chip) (33).”
BackgroundAzole Binding Properties of Candida albicans Sterol 14-α Demethylase (CaCYP51)
Warrilow, A. G. S., Martel, C. M., Parker, J. E., Melo, N., Lamb, D. C., Nes, W. D., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00587-10 · Cited by 112 · cited 1×
“Point mutations in the ERG11 gene result in reduced binding affinity of azoles to their target without precluding enzymatic function (31).”
BackgroundHoot, S. J., Smith, A. R., Brown, R. P., & White, T. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00995-10 · Cited by 107 · cited 1×
“Previous studies show that activating mutations in Upc2 result in increased expression of ERG11 and decreased fluconazole susceptibility; however, only three substitutions (G648D, A643T, and A643V) in Upc2 have been identified in clinical isolates that contribute to azole resistance (7, 11, 12).”
BackgroundA complex network of RNA–RNA interactions controls subgenomic mRNA transcription in a tombusvirus
Lin, H., & White, K. A. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600336 · Cited by 66 · cited 1×
“Ergosterol was extracted and quantified as described previously (16).”
MethodCytoplasmic localization of sterol transcription factors Upc2p and Ecm22p in S. cerevisiae
Marie, C., Leyde, S., & White, T. C. (2008) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2008.07.004 · Cited by 47 · cited 1×
“cerevisiae shows that ScUpc2 and ScEcm22 are localized to intracellular membranes outside the nucleus, and under sterol-depleting conditions, perinuclear localization is increased (20).”
Background
Cited by
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“albicans clinical isolates demonstrated 47 of these isolates overexpressed ERG11 by at least 2-fold (Flowers et al., 2012).”
BackgroundMethodSelf-citationAntifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“…of C. albicans suggests that CDR1/CDR2 up-regulation is more prevalent than ERG11 or MDR1 up-regulation, with combinations of CDR1/CDR2 up-regulation and ERG11 alterations as the most common (Goldman et al. 2004; Park and Perlin 2005; Coste et al. 2007; Siikala et al. 2010; Flowers et al. 2012).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D.
- Affiliations
- University of Tennessee Health Science Center (US)
- Medical Diagnostic Laboratories (United States) (US)
- University of Würzburg (DE)
- ORCID
- Venue
- Eukaryotic Cell
- Publisher
- American Society for Microbiology
- Published
- 2012-10
- Volume
- 11
- Issue
- 10
- Pages
- 1289-1299
- ISSN
- 1535-9778 (ISSN-L)
- 1535-9786
- PMC
- PMC3485914
- OpenAlex
- W2169755129
- Cited by
- 239
- References
- 32
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 25 · 2023: 22 · 2022: 19 · 2021: 22 · 2020: 21 · 2019: 23 · 2018: 11 · 2017: 20 · 2016: 9 · 2015: 14 · 2014: 16 · 2013: 11
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Eukaryotic Cell (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI058145)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, UPC2, ERG11, fluconazole resistance, azole resistance, gain-of-function mutations, zinc cluster transcription factors, ergosterol biosynthesis, transcriptional regulation, clinical isolates, antifungal resistance
- MeSH terms
- Antifungal Agents, Candida albicans, Cytochrome P-450 Enzyme System, Ergosterol, Fungal Proteins, Transcription Factors, Transcription, Genetic, Fluconazole, Up-Regulation, Genome, Fungal, Mutation, Missense, ATP Binding Cassette Transporter, Subfamily B, Member 1, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.